161 related articles for article (PubMed ID: 33468887)
21. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.
Hughes KS; Schnaper LA; Berry D; Cirrincione C; McCormick B; Shank B; Wheeler J; Champion LA; Smith TJ; Smith BL; Shapiro C; Muss HB; Winer E; Hudis C; Wood W; Sugarbaker D; Henderson IC; Norton L; ; ;
N Engl J Med; 2004 Sep; 351(10):971-7. PubMed ID: 15342805
[TBL] [Abstract][Full Text] [Related]
22. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Buzdar AU;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
[TBL] [Abstract][Full Text] [Related]
23. Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer.
Sohn G; Ahn SH; Kim HJ; Son BH; Lee JW; Ko BS; Lee Y; Lee SB; Baek S
Cancer Res Treat; 2016 Oct; 48(4):1351-1362. PubMed ID: 27063654
[TBL] [Abstract][Full Text] [Related]
24. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.
Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632
[TBL] [Abstract][Full Text] [Related]
25. Current status of endocrine therapy for breast cancer.
Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
Breast Cancer; 2003; 10(2):105-11. PubMed ID: 12736562
[TBL] [Abstract][Full Text] [Related]
26. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.
Yamashita H; Yando Y; Nishio M; Zhang Z; Hamaguchi M; Mita K; Kobayashi S; Fujii Y; Iwase H
Breast Cancer; 2006; 13(1):74-83. PubMed ID: 16518065
[TBL] [Abstract][Full Text] [Related]
28. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
29. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
30. [A case of recurrent breast cancer with multiple lung, adrenal, inferior vena cava tumor thrombus and bone metastases successfully treated with 5'-DFUR and hormonal therapy].
Sakamoto E; Hasegawa H; Komatsu S; Hiromatsu T; Itazu K; Tabata T; Kawai K; Fukami Y
Gan To Kagaku Ryoho; 2005 Apr; 32(4):539-42. PubMed ID: 15853224
[TBL] [Abstract][Full Text] [Related]
31. [A Case of an Elderly with Locoregional Recurrence of ER-Negative HER2-Positive Breast Cancer Successfully Treated with Local Therapy].
Yoshioka S; Hojo S; Toyoda Y; Ito Y; Fukata T; Miyagaki H; Nishida H; Shingai T; Takayama O; Fukuzaki T; Ohigashi H
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2232-2234. PubMed ID: 30692341
[TBL] [Abstract][Full Text] [Related]
32. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
33. [A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy].
Baba S; Oji Y; Teramoto M; Kawabata K; Saito A
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1905-6. PubMed ID: 19920398
[TBL] [Abstract][Full Text] [Related]
34. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy.
Buchholz TA; Tucker SL; Erwin J; Mathur D; Strom EA; McNeese MD; Hortobagyi GN; Cristofanilli M; Esteva FJ; Newman L; Singletary SE; Buzdar AU; Hunt KK
J Clin Oncol; 2001 Apr; 19(8):2240-6. PubMed ID: 11304777
[TBL] [Abstract][Full Text] [Related]
35. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
36. [A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy].
Oda G; Nakagawa T; Sato T; Kuwayama T; Yamamoto K; Kawachi H; Kubota K; Sugihara K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2753-5. PubMed ID: 21224702
[TBL] [Abstract][Full Text] [Related]
37. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
38. [A Long-Surviving Case of Locally Advanced Breast Cancer with Multiple Lung Metastasis].
Satoh E; Innami Y; Uehira D; Yonekura K; Murakata A; Ohinata R; Toyofuku Y; Tanami H; Osanai T; Sugano N; Sakoma T
Gan To Kagaku Ryoho; 2024 Apr; 51(4):427-429. PubMed ID: 38644311
[TBL] [Abstract][Full Text] [Related]
39. Reducing the risk of late recurrence in hormone-responsive breast cancer.
Cufer T
Ann Oncol; 2007 Sep; 18 Suppl 8():viii18-25. PubMed ID: 17890210
[TBL] [Abstract][Full Text] [Related]
40. Never too late: reducing late breast cancer relapse risk.
Harbeck N
Curr Med Res Opin; 2008 Dec; 24(12):3295-305. PubMed ID: 18954499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
